Tribute Pharmaceuticals Canada's quarterly market cap
increased
from Mar. 2015 ($71.93 Mil) to Jun. 2015 ($181.32 Mil) but then
declined
from Jun. 2015 ($181.32 Mil) to Sep. 2015 ($100.99 Mil).
Tribute Pharmaceuticals Canada's annual market cap
increased
from Dec. 2012 ($13.86 Mil) to Dec. 2013 ($18.39 Mil) and
increased
from Dec. 2013 ($18.39 Mil) to Dec. 2014 ($43.46 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Tribute Pharmaceuticals Canada's Enterprise Value for Today is $117.40 Mil.
Tribute Pharmaceuticals Canada Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Tribute Pharmaceuticals Canada's Market Cap
For the Drug Manufacturers - Specialty & Generic subindustry, Tribute Pharmaceuticals Canada's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tribute Pharmaceuticals Canada's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tribute Pharmaceuticals Canada's Market Cap distribution charts can be found below:
* The bar in red indicates where Tribute Pharmaceuticals Canada's Market Cap falls into.
Tribute Pharmaceuticals Canada Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tribute Pharmaceuticals Canada (OTCPK:TBUFF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Tribute Pharmaceuticals Canada Market Cap Related Terms
Thank you for viewing the detailed overview of Tribute Pharmaceuticals Canada's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Business Description
Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TBUFF has been successfully added to your 